IRIS
CIGLIANO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.546
AS - Asia 2.462
SA - Sud America 1.690
EU - Europa 1.183
AF - Africa 102
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.998
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.435
BR - Brasile 1.488
SG - Singapore 1.083
CN - Cina 635
UA - Ucraina 424
HK - Hong Kong 256
DE - Germania 205
IT - Italia 164
VN - Vietnam 150
FI - Finlandia 79
AR - Argentina 76
SE - Svezia 68
GB - Regno Unito 58
IQ - Iraq 44
CA - Canada 42
EC - Ecuador 40
ID - Indonesia 35
BD - Bangladesh 33
IN - India 33
MX - Messico 32
TR - Turchia 32
FR - Francia 31
RU - Federazione Russa 30
MA - Marocco 26
ZA - Sudafrica 26
UZ - Uzbekistan 22
CZ - Repubblica Ceca 21
PK - Pakistan 20
VE - Venezuela 20
BE - Belgio 19
JP - Giappone 18
PY - Paraguay 18
AT - Austria 16
KR - Corea 15
PL - Polonia 15
CO - Colombia 14
NL - Olanda 13
PE - Perù 13
DZ - Algeria 11
CL - Cile 10
KE - Kenya 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
AZ - Azerbaigian 8
ES - Italia 8
EG - Egitto 7
IL - Israele 7
TN - Tunisia 7
EU - Europa 6
JO - Giordania 6
LT - Lituania 6
NP - Nepal 6
PA - Panama 6
UY - Uruguay 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
IR - Iran 5
JM - Giamaica 5
PS - Palestinian Territory 5
BO - Bolivia 4
GR - Grecia 4
HN - Honduras 4
KZ - Kazakistan 4
LB - Libano 4
RO - Romania 4
RS - Serbia 4
SA - Arabia Saudita 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AL - Albania 3
AM - Armenia 3
BG - Bulgaria 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
GE - Georgia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
NI - Nicaragua 3
BY - Bielorussia 2
IE - Irlanda 2
NG - Nigeria 2
OM - Oman 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
ML - Mali 1
MQ - Martinica 1
Totale 9.989
Salva come PNG Salva come JPEG
Città #
Dallas 1.816
Chandler 645
Singapore 572
Hong Kong 254
Jacksonville 225
Princeton 184
Beijing 182
Ashburn 142
New York 108
São Paulo 108
Nanjing 102
Sassari 88
Ann Arbor 79
Wilmington 64
Rio de Janeiro 56
Ho Chi Minh City 55
Shanghai 47
Los Angeles 45
Santa Clara 42
Belo Horizonte 41
Dearborn 41
Boardman 40
Nanchang 36
Munich 30
Hanoi 27
Helsinki 27
Curitiba 25
Mountain View 25
The Dalles 24
Shenyang 22
Woodbridge 22
Baghdad 21
Changsha 21
Tashkent 21
Tianjin 21
Brasília 20
Columbus 20
San Francisco 20
Brussels 19
Buffalo 18
Campinas 18
Council Bluffs 18
Porto Alegre 18
Brno 17
Guayaquil 17
Houston 17
Ribeirão Preto 16
Tokyo 16
Toronto 16
Atlanta 15
Hebei 15
Seoul 15
Andover 14
Jiaxing 14
Salvador 14
Zhengzhou 14
Denver 13
Guarulhos 13
Johannesburg 13
Montreal 13
Norwalk 13
Warsaw 13
Goiânia 12
London 12
Betim 11
Fortaleza 11
Jinan 11
Nuremberg 11
Osasco 11
Quito 11
Santo André 11
Chennai 10
Dhaka 10
Juiz de Fora 10
Kunming 10
Manaus 10
Ningbo 10
Recife 10
Asunción 9
Blumenau 9
Boston 9
Campo Grande 9
Joinville 9
Lima 9
Mexico City 9
Nairobi 9
Brooklyn 8
Casablanca 8
Fairfield 8
Falls Church 8
Guangzhou 8
Orem 8
Phoenix 8
Poplar 8
Stockholm 8
São Gonçalo 8
Taubaté 8
Uberlândia 8
Algiers 7
Baku 7
Totale 6.040
Salva come PNG Salva come JPEG
Nome #
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 324
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 230
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 223
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and biological evaluation 194
A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. IF 2009: 4.522 JCR: Q1 180
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. 170
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 168
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes 161
Apolipoprotein Profiles in Atherosclerotic Disease 160
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 160
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 157
Apolipoprotein profiles in atherosclerotic disease 152
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 147
Association between human plasma chondroitin sulphate isomers and carotid atherosclerotic plaque 144
Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in decellularized porcine scaffolds for tissue engineering purposes 143
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver 142
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 139
Apolipoprotein Profiles in Atherosclerotic Disease 136
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 133
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes 130
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 126
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 126
Apolipoprotein profiles in atherosclerotic disease 125
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma 122
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 120
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 118
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoing carotid endarterectomy 118
Differential distribution of structural components and hydration in aortic and pulmonary heart valve conduits: Impact of detergent-based cell removal. IF 2010: 4.824 JCR: Q1 118
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype 114
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 114
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 113
Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development 113
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 112
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 112
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans 110
Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1 110
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoingcarotid endarterectomy 106
SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 106
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma 98
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans 96
Structural analisys of plasma glycosaminoglycans in patients with atheromatous lesions 93
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 92
PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. 91
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis 89
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis 89
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. 89
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 88
Pivotal role of fatty acid synthase in c-myc driven hepatocarcinogenesis 88
Glycosaminoglycan content and distribution in human normal and varicose veins 86
Corrigendum to ‘TAZ is indispensable for c-MYC-induced hepatocarcinogenesis’ [J Hepatol (2022) 123–134] (Journal of Hepatology (2022) 76(1) (123–134), (S016882782102016X), (10.1016/j.jhep.2021.08.021)) 86
Erratum: Frizzled-10 extracellular vesicles plasma concentration is associated with tumoral progression in patients with colorectal and gastric cancer (Journal of Oncology (2019) 2019 (2715968) DOI: 10.1155/2019/2715968) 86
PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells 85
New Capillary Zone Electrophoresis (CZE) method for glycosaminoglycan analysis 85
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and antileukemia evaluation 83
Loss of pten synergizes with c-met to promote hepatocellular carcinoma development via mTORC2 pathway 83
The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans 80
Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase 80
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease 79
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 79
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 79
Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. 79
Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression 79
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. 78
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 77
TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma 76
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice 76
Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles 74
GLYCOSAMINOGLYCAN DIVERSITY IN MARINE SPONGE EXTRACELLULAR MATRIX 73
Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice 73
Role of the Notch signaling in cholangiocarcinoma 72
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 71
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model 70
Glycosaminoglycan diversity in marine sponge extracellular matrix 70
Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium 70
Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer 70
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges 69
Molecular and metabolic changes in human clear cell liver foci 69
Human serum albumin Cys34 oxidative modifications after infiltration in the carotid atherosclerotic plaque 68
Functional role of SGK3 in PI3K/Pten driven liver tumor development 68
Ultrasensitive Capillary Zone Electrophoresis (CZE) for glycosaminoglycan analisys in normal human plasma 68
Glycosaminoglycans and fabry’s disease 68
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma 67
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma 66
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 65
Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation 63
Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans 63
Structural analysis of plasma glycosaminoglycans in patients undergoing carotid endarterectomy 61
Structural analysis of glycosaminoglycans from fresh porcine aortic valves 61
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 61
Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair 61
Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism 60
Human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 59
eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma 58
TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives 58
Current challenges to underpinning the genetic basis for cholangiocarcinoma 57
Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice 56
Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique 50
Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. 49
Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans 49
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment 44
Totale 10.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021331 0 0 0 0 0 29 84 4 91 83 33 7
2021/2022479 37 3 2 4 13 10 21 28 45 24 81 211
2022/20231.114 116 115 48 178 106 167 0 113 189 7 40 35
2023/2024299 52 18 5 13 83 37 2 14 0 5 29 41
2024/20253.002 26 28 175 73 152 87 208 484 1.094 450 144 81
2025/20263.694 253 1.157 1.059 728 454 43 0 0 0 0 0 0
Totale 10.105